MAPT and Alzheimer disease: Overall, for non-AD, Aβ42 had 38% specificity, T-tau had 79% specificity, P-tau and Aβ42/Aβ40 had 86% specificity, and P-tau/Aβ42 had 83% specificity (Table 1 shows details by individual variants).